ReviewMaterials (Basel, Switzerland)2019
The Tumor-on-Chip: Recent Advances in the Development of Microfluidic Systems to Recapitulate the Physiology of Solid Tumors.
Review in Materials (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Tumor-on-chip and cancer microphysiological platforms: knowledge structure, thematic evolution, and the emergence of organoid-integrated models, 2010-2025.Frontiers in pharmacology · 2026Pooled it
- Bridging Organ-on-a-Chip and Omics: A Multi-Dimensional Frontier in Biomedical Research.Biotechnology and bioengineering · 2026Review
- PK-Informed Microphysiological Systems: From Dynamic Dosing to Quantitative In Vitro-In Vivo Translation.Pharmaceutics · 2026Review
- Uncovering the Potential of 3D Spheroids for Modeling the Cellular Crosstalk Within the Tumor Microenvironment in HNSCC.Biotechnology journal · 2026Review
- Patient-derived ependymoma and medulloblastoma tumoroids: generation, biobanking and drug screening.Nature protocols · 2026Review
- Recapitulating In Vivo Pharmacokinetics and Size-Dependent Nanomedicine Delivery in a Microfluidic Platform.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- The promising applications of 3D printing technology for diagnosis and therapy of cancer: Recent advances and challenges.BioImpacts : BI · 2026Review
- Development of a 3D Human Colon Model Along with Bioelectronics for the Induction and Monitoring of Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The role of 3D culture models and advanced chromatography in exosome research for triple-negative breast cancer.Journal of the Egyptian National Cancer Institute · 2025Review
- Impact of Fiber Orientation in Electrospun PLA Scaffolds on Fluid Dynamics in a Custom Microfluidic Device.Advanced healthcare materials · 2025Article
- Exploring the Complexity of Cutaneous Squamous CellCarcinoma Microenvironment: Focus on Immune Cell Roles by Novel 3D In Vitro Models.Life (Basel, Switzerland) · 2025Review
- Review
- Nanomedicine in Cancer Therapeutics: Current Perspectives from Bench to Bedside.Molecular cancer · 2025Review
- Review
- Immune-Infiltrated Cancer Spheroid Model with Vascular Recirculation Reveals Temporally Dependent and Tissue-Specific Macrophage Recruitment.Advanced healthcare materials · 2025Article
- Tumor-microenvironment-on-a-chip: the construction and application.Cell communication and signaling : CCS · 2024Review
- Cancer Patient-Derived Cell-Based Models: Applications and Challenges in Functional Precision Medicine.Life (Basel, Switzerland) · 2024Review
- Exploring Importance and Regulation of Autophagy in Cancer Stem Cells and Stem Cell-Based Therapies.Cells · 2024Review
- Article
- Cell Membrane Fragment-Wrapped Parenteral Nanoemulsions: A New Drug Delivery Tool to Target Gliomas.Cells · 2024Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The ideal in vitro recreation of the micro-tumor niche-although much needed for a better understanding of cancer etiology and development of better anticancer therapies-is highly challenging. Tumors are complex three-dimensional (3D) tissues that establish a dynamic cross-talk with the surrounding tissues through complex chemical signaling. An extensive body of experimental evidence has established that 3D culture systems more closely recapitulate the architecture and the physiology of human solid tumors when compared with traditional 2D systems. Moreover, conventional 3D culture systems fail to recreate the dynamics of the tumor niche. Tumor-on-chip systems, which are microfluidic devices that aim to recreate relevant features of the tumor physiology, have recently emerged as powerful tools in cancer research. In tumor-on-chip systems, the use of microfluidics adds another dimension of physiological mimicry by allowing a continuous feed of nutrients (and pharmaceutical compounds). Here, we discuss recently published literature related to the culture of solid tumor-like tissues in microfluidic systems (tumor-on-chip devices). Our aim is to provide the readers with an overview of the state of the art on this particular theme and to illustrate the toolbox available today for engineering tumor-like structures (and their environments) in microfluidic devices. The suitability of tumor-on-chip devices is increasing in many areas of cancer research, including the study of the physiology of solid tumors, the screening of novel anticancer pharmaceutical compounds before resourcing to animal models, and the development of personalized treatments. In the years to come, additive manufacturing (3D bioprinting and 3D printing), computational fluid dynamics, and medium- to high-throughput omics will become powerful enablers of a new wave of more sophisticated and effective tumor-on-chip devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.